Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis-Reference-Cited by-同舟云学术

Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis

Published:2019-05-17 Issue:9 Volume:38 Page:2451-2459
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Takahashi Nobunori^ORCID,Kojima Toshihisa,Kida Daihei,Kaneko Atsushi,Hirano Yuji,Fujibayashi Takayoshi,Yabe Yuichiro,Takagi Hideki,Oguchi Takeshi,Hanabayashi Masahiro,Kato Takefumi,Funahashi Koji,Hayashi Masatoshi,Tsuboi Seiji,Kanayama Yasuhide,Sobue Yasumori,Asai Nobuyuki,Matsumoto Takuya,Watanabe Tatsuo,Asai Shuji,Ishiguro Naoki

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s10067-019-04581-7.pdf

Reference24 articles.

1. Smolen JS, Landewe R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960–977

2. Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol (Hoboken, NJ) 68(1):1–26

3. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Mola EM, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet (London, England) 363(9410):675–681

4. Kaneko A, Hirano Y, Fujibayashi T, Hattori Y, Terabe K, Kojima T, Ishiguro N (2013) Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice. Mod Rheumatol 23(3):466–477

5. Hattori Y, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Terabe K, Yabe Y, Miyake H, Kato T, Takagi H, Hayashi M, Ito T, Kanayama Y, Oguchi T, Takahashi N, Ishikawa H, Funahashi K, Ishiguro N (2016) Longterm retention rate and risk factors for adalimumab discontinuation due to efficacy and safety in Japanese patients with rheumatoid arthritis: an observational cohort study. J Rheumatol 43(8):1475–1479

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Associations of frailty with RA-ILD and poor control of disease activity in patients with rheumatoid arthritis: A multi-center retrospective observational study;Journal of Orthopaedic Science;2023-12

2. Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis;Scientific Reports;2023-09-14

3. Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study;Pediatric Rheumatology;2022-11-14

4. Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI study;Modern Rheumatology;2022-04-07

5. Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure;Therapeutic Advances in Musculoskeletal Disease;2022-01